Weakness in Proteomics and Life Science Research Contributes to Disappointing Q2 for Waters
July 29, 2011
Weakness in Proteomics and Life Science Research Contributes to Disappointing Q2 for Waters
The firm's revenues were up 14 percent for the quarter but missed Wall Street's estimates due in part to softness in government and academic research and orders delayed in anticipation of the launch of its new Synapt G2-S mass spec.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Waters' Q1 Revenues Jump 16 Percent on Strong Mass Spec and LC Sales
April 29, 2011 / ProteoMonitor - High-End Mass Spec Sales Drive Double-Digit Q4 Growth at Waters, AB Sciex
January 28, 2011 / ProteoMonitor - Instrument Vendors Focus on UPLC and Triple-Quad, Qual-Quan MS at JP Morgan Conference
January 14, 2011 / ProteoMonitor - Proteomics Expectations Bear Fruit in 2010, But Challenges Remain
January 7, 2011 / ProteoMonitor - Waters Says Switching to UHPLC Could Trigger Significant Growth In Instrument Business
October 29, 2010 / ProteoMonitor